CaroGen

Farmington, United States· Est. 2016

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $20M

Overview

CaroGen is a private, pre-clinical-stage biotech developing immunotherapies using its innovative AVIDIO platform, an RNA-based artificial virus technology capable of delivering multiple transgenes to elicit broad immune responses. Its pipeline features two late-stage pre-clinical candidates: CARG-2020 for ovarian cancer and CARG-201 for chronic hepatitis B (CHB). The company is backed by significant non-dilutive funding from the NIH and DoD, exceeding $16 million for its HBV program, and holds a broad patent portfolio covering composition of matter and methods of use.

OncologyInfectious Diseases

Technology Platform

AVIDIO Platform: An RNA-based artificial virus platform (virus-like vesicle/VLV) capable of delivering multiple transgenes to elicit broad-spectrum innate and adaptive immune responses.

Funding History

Total raised:$20M

Series A$15MNorthpond VenturesOct 15, 2023

Seed$5MYale UniversityJun 15, 2022

Opportunities

CaroGen's AVIDIO platform addresses massive markets with high unmet need: a functional cure for chronic hepatitis B (250M+ patients) and novel immunotherapy for recurrent ovarian cancer.

The platform's versatility also allows for expansion into other infectious diseases (e.g., universal flu) and oncology indications.

Strong non-dilutive grant funding de-risks early development and extends runway.

Risk Factors

The company faces high clinical development risk as its lead programs are pre-clinical, with unproven safety/efficacy in humans.

Future capital needs for clinical trials are significant and may require dilutive financing or partnerships.

The competitive landscapes in immuno-oncology and HBV therapeutics are intensely crowded with well-resourced players.

Competitive Landscape

In HBV, CaroGen competes with large pharma (GSK, Gilead, Janssen) and biotechs (Arbutus, Vir) developing combination regimens for a functional cure. In ovarian cancer immuno-oncology, competition includes checkpoint inhibitors, ADC developers, and other viral/oncolytic therapies. CaroGen's differentiation lies in its unique RNA-based artificial virus platform designed to deliver multi-antigen immune responses.